HelloOutThere @unclemacro - Twitter Profile

$ABCL 🚨 AbCellera announces positive top line ph2 results for ABCL635, a GPCR targeting antibody: - Phase 2 results showed best-in-class reductions in both frequency and severity of moderate-to-severe vasomotor symptoms after a single dose - ABCL635 significantly improved sleep and patient global impression of change - ABCL635 demonstrated a favorable tolerability profile “ABCL635 reduced VMSM-S frequency compared to placebo, with an 8.8 mean reduction in the number of moderate and severe events per day from baseline at week 4 (Day 29) compared to 3.5, showing a mean placebo-adjusted treatment difference of 5.3 (p<0.001). The mean percent reduction at week 4 for VMSM-S frequency was 83% for the ABCL635 treatment group versus a 33% reduction for placebo, leading to a mean placebo-adjusted treatment difference of 50%.” “ABCL635 also resulted in improvement in VMSM-S severity compared to placebo, with a mean reduction of 1.4 points at week 4 compared to 0.3, and a mean placebo-adjusted treatment difference of 1.1 (p<0.001). The mean percent reduction in VMSM-S severity from baseline to week 4 was 58% in the ABCL635 group compared to 12% in the placebo group, leading to a mean placebo-adjusted treatment difference of 46%.” “Meaningful improvements were also observed in patient sleep scores and patient global impression of change.” "These positive results represent a significant milestone for women's health and for AbCellera" said Sarah Noonberg, M.D., Ph.D., Chief Medical Officer of AbCellera. "By successfully targeting the NK3 receptor with an antibody, we have demonstrated potential best-in-class vasomotor symptom relief over four weeks with a single subcutaneous dose. These data indicate that ABCL635 could offer menopausal women a well-tolerated, long-acting treatment that has the potential to markedly improve their quality of life." Congratulations to AbCellera and all shareholders!!!!